Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab versus sorafenib in first-line unresectable hepatocellular carcinoma
NCT03412773Phase 3Completed
- Sponsor
- BeiGene
- Start
- Dec 2017
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by BeiGene. Started Dec 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03412773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412773.